biostudies-literatureUnknown177(1)Strange C<h4>Rationale</h4>The presence of inflammatory cells on bronchoalveolar lavage is often used to predict disease activity and the need for therapy in systemic sclerosis-associated interstitial lung disease.<h4>Objectives</h4>To evaluate whether lavage cellularity identifies distinct subsets of disease and/or predicts cyclophosphamide responsiveness.<h4>Methods</h4>Patients underwent baseline lavage and/or high-resolution computed tomography as part of a randomized placebo-controlled trial of cyclophosphamide versus placebo (Scleroderma Lung Study) to determine the effect of therapy on forced vital capacity. Patients with 3% or greater polymorphonuclear and/or 2% or greater eosinophilic leukocytes on lavage and/or ground-glass opacification on computed tomography were eligible for enrollmentAmerican journal of respiratory and critical care medicine91-8https://www.ebi.ac.uk/biostudies/studies/S-EPMC2176114biostudies-literatureBronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease.PMC2176114Furst DESilver RMElashoff RMGoldin JChung JSuh RSmith EABolster MBScleroderma Lung Study Research GroupTashkin DPClements PTheodore AStrange CRoth MDfalseBronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease.<h4>Rationale</h4>The presence of inflammatory cells on bronchoalveolar lavage is often used to predict disease activity and the need for therapy in systemic sclerosis-associated interstitial lung disease.<h4>Objectives</h4>To evaluate whether lavage cellularity identifies distinct subsets of disease and/or predicts cyclophosphamide responsiveness.<h4>Methods</h4>Patients underwent baseline lavage and/or high-resolution computed tomography as part of a randomized placebo-controlled trial of cyclophosphamide versus placebo (Scleroderma Lung Study) to determine the effect of therapy on forced vital capacity. Patients with 3% or greater polymorphonuclear and/or 2% or greater eosinophilic leukocytes on lavage and/or ground-glass opacification on computed tomography were eligible for enrollment2008-01-01T00:00:00Z2008 Jan2025-04-04T08:38:44.488Z2019-03-27T02:22:25ZS-EPMC21761141790141410.1164/rccm.200705-655OC10.1164/rccm.200705-655oc